



Medicine Supply Notification

MSN/2021/031

Kolanticon gel[®] (2.5mg dicycloverine hydrochloride, 200mg aluminium hydroxide, 100mg light magnesium oxide, 20mg simethicone per 5ml)

Tier 2 – medium impact* Date of issue: 16/06/2021

Summary

Kolanticon gel[®] is out of stock until January 2022.

 Alternative preparations for symptomatic relief of gastro-intestinal disorders characterised by hyperacidity, smooth muscle spasm, including irritable bowel syndrome (IBS), and flatulence, remain available.

Actions Required

Where patients have insufficient supplies to last until the re-supply date, clinicians should consider the following;

- review if treatment is still required;
- consider switching patients to alternative preparations (see supporting information below); and
- counsel patients on the different product and dosing regimen prescribed.

Supporting information

Clinical Information

Kolanticon gel is licensed for the treatment and prophylaxis of symptoms of peptic ulcer and functional dyspepsia especially in patients in whom gastric distress results from hyperacidity, smooth muscle spasm, including IBS, and flatulence, as well as symptomatic relief in oesophagitis, hiatus hernia, gastritis and iatrogenic gastritis.

The components of Kolanticon consist of an antacid (magnesium and aluminium), antispasmodic (dicloverine) and antiflatulence agent (simethicone). Although there is no direct equivalent product to Kolanticon Gel® on the UK market, there are alternatives to the components of Kolanticon and choice will depend on symptom(s) being treated. More than one product may be needed if treating more than one symptom. Refer to BNF chapters on antacids and NICE CKS guidance on IBS for further information.

Please refer to SPC for further information: -

- Kolanticon Gel ®

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.